Delivery Order SPE2DB20D1100-SPE2DB25FE0VA
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,001.53 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This firm fixed-price delivery order was competitively awarded without a set-aside designation and is scheduled for completion by August 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the...
- The Defense Logistics Agency awarded a delivery order valued at $1,551.16 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count units) on August 29, 2025, with completion scheduled for September 2, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of the companies' long-standing relationship supporting...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,518.00 firm-fixed-price delivery order to AmerisourceBergen Drug Corp's Corporate Office division for the supply of 4,565,497,445 units of Febuxostat 40 mg tablets. This delivery order is part of a larger indefinite delivery contract (IDC) with DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for a comprehensive range of pharmaceutical and medical supplies to support military treatment programs and facilities...
- The Defense Logistics Agency awarded a delivery order valued at $4,747.98 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets in quantities of 30, with an ultimate completion date of August 11, 2025. This contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $2,768.65 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count units) on September 4, 2025, with completion scheduled for September 5, 2025. This delivery order represents a firm fixed price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $8,292.13 and an ultimate completion date of August 27, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Febuxostat 40 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with a ceiling value of $1,394.19, with an ultimate completion date of August 15, 2025. The contract involves no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Febuxostat 80 mg tablets in quantities of 30, with a contract ceiling value of $1,191.79. This is a firm fixed price delivery order with an ultimate completion date of August 21, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a delivery order valued at $1,972.23 to AmerisourceBergen Drug Corp for Febuxostat 40 mg tablets (30-count packages) on September 11, 2025, with an ultimate completion date of September 12, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order valued at $1,629.42 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets (30-count packages). This firm fixed-price, non-set-aside delivery order was executed on August 18, 2025, with an ultimate completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0VADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,527.89 to AmerisourceBergen Drug Corp for the supply of Febuxostat 40 mg tablets in a quantity of 30s. The contract, awarded on September 23, 2025, with an ultimate completion date of September 24, 2025, is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a critical prime vendor for federal pharmaceutical procurement, supplying a comprehensive range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs and the Defense Health Agency. The company's extensive federal contract portfolio demonstrates its established capability to fulfill diverse medical supply requirements across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/23/25 |